Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myovant Sciences Ltd (NY: MYOV )

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Mar 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myovant Sciences Ltd

< Previous 1 2 3 4 5 Next >
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
From Myovant Sciences, Inc.
Via GlobeNewswire
MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
From Kahn Swick & Foti, LLC
Via Business Wire
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
From Myovant Sciences, Inc.
Via GlobeNewswire
Myovant Sciences: Q2 Earnings Insights
Myovant Sciences (NYSE:MYOV) reported its Q2 earnings results on Wednesday, October 26, 2022 at 08:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Where Myovant Sciences Stands With Analysts
Myovant Sciences (NYSE:MYOV) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
From Myovant Sciences, Inc.
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Myovant Sciences Ltd. (NYSE - MYOV), ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SPNE), LogicBio Therapeutics, Inc. (Nasdaq – LOGC),
From Brodsky & Smith LLC
Via GlobeNewswire
Looking Into Myovant Sciences's Return On Invested Capital
Benzinga Pro data, Myovant Sciences (NYSE:MYOV) reported Q2 sales of $104.82 million. Earnings fell to a loss of $45.62 million, resulting in a 114.79% decrease from last quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
Upgrades 
Via Benzinga
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
From Myovant Sciences, Inc.
Via GlobeNewswire
MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
From Kahn Swick & Foti, LLC
Via Business Wire
Earnings Outlook For Myovant Sciences
Myovant Sciences (NYSE:MYOV) is set to give its latest quarterly earnings report on Wednesday, 2022-10-26. Here's what investors need to know before the announcement. Analysts estimate that Myovant... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022
Upgrades 
Via Benzinga
US Stock Futures Down; Big Tech Earnings In Focus
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Tuesday after recording gains in the previous session. The Dow Jones jumped by more than 400 points on Monday after all the... 
Via Benzinga
Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. 
Via Benzinga
Avis Budget, Scholastic And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones gaining over 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Myovant Sciences Cancels Second Quarter Earnings Conference Call
From Myovant Sciences, Inc.
Via GlobeNewswire
Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session
Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety,... 
Via Benzinga
BYND Stock Alert: What to Know as Beyond Meat Launches Plant-Based Steak Product
Beyond Meat (BYND) stock is on the move Monday after the company revealed Beyond Steak, a new plant-based steak product. 
Via InvestorPlace
MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences
Acquisition announcements can cause explosive share-price moves, and MYOV stock is spiking in the wake of a big-dollar buyout announcement. 
Via InvestorPlace
US Stocks Mixed; Dow Jumps 200 Points
U.S. stocks traded mixed this morning, with the Dow Jones surging around 200 points on Monday. 
Via Benzinga
Why Myovant Sciences Stock Is Moving Higher
Myovant Sciences Ltd (NYSE: MYOV) shares are trading higher Monday after the company announced it will be acquired by Sumitovant Biopharma for $27 per share in cash. 
Via Benzinga
Tesla Slashes China EV Prices, TSMC Joins Embargo After NVIDIA and AMD, Schlumberger Rebrands As SLB: Top Stories Monday, Oct. 24
Benzinga 
Via Benzinga
MYOV STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Myovant Sciences Ltd. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Myovant Sciences And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) rose 70.8% to $0.41 in pre-market trading. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. 
Via Benzinga
US Stock Futures Lower Following Friday's Rally; Tesla In Focus
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording sharp gains in the previous session. The Dow Jones jumped by around 750 points on Friday. All the... 
Via Benzinga
Myovant Sciences, Discover Financial And 3 Stocks To Watch Heading Into Monday
With US stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Myovant Agrees To Be Acquired By Sumitomo Pharma Unit In $1.7B Deal As Japanese Company Sweetens Bid
Myovant Sciences, Inc. (NYSE: MYOV) announced late Sunday a deal to be acquired by Japanese pharmaceutical company Sumitomo Pharma Co., Ltd's (OTC: DNPUF) unit Sumitovant Biopharma. 
Via Benzinga
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
From Myovant Sciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.